Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postmarketing Study of AO-128 (Voglibose) in Impaired Glucose Tolerance
NCT02287402Phase 4Completed
- Sponsor
- Takeda
- Start
- Mar 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of voglibose in impaired glucose tolerance (IGT), sponsored by Takeda. Primary endpoints: Assessment of Diabetic Status in the Treatment Period up to 122 weeks and Assessment of Diabetic Status in Follow-up at Week 48. Started Mar 2010; status: completed.
02
Drugs
voglibose
03
Conditions
impaired glucose tolerance (IGT)
Beyond the preview
Go deeper on NCT02287402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287402.